<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03446456</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00076723</org_study_id>
    <nct_id>NCT03446456</nct_id>
  </id_info>
  <brief_title>Vasopressin and Pain Perception in the Brain</brief_title>
  <official_title>The Influence of Vasopressin on Observational Learning of Placebo Analgesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The feeling of pain is not just a sensory experience, but is also influenced by emotions,
      beliefs and expectations, making pain a highly subjective experience. This is evident in
      clinical practice, where the behavior of the physician and the treatment context can strongly
      influence the pain experience of patients. Research has shown that patients' expectation that
      a treatment will reduce pain influences individual perception of pain, even if the treatment
      has no active ingredient. The expectancy-induced analgesia emerges due to a modulation of the
      individual pain experience of patients by an engagement of endogenous inhibitory systems in
      the central nervous system.

      The development of expectancy-induced analgesia can be generated in several ways. The
      investigators have previously demonstrated that social information and observational learning
      (e.g. the patient observes analgesia in another person receiving a treatment) can lead to
      expectancy-induced analgesia and pain reduction. However, the neural mechanisms (mechanisms
      in the brain) of how these expectancies are acquired and the neural mechanisms of analgesia
      induced by observational learning are unknown.

      The investigators recently established a procedure to investigate neural mechanisms of
      observational learning in placebo analgesia. Here the investigators propose to investigate
      the influence of vasopressin, a neurotransmitter that is important for social interaction, on
      observational learning.

      The investigators will use functional magnetic resonance imaging (fMRI), a non-invasive
      method, to investigate neural activity in humans. Participants will either receive
      vasopressin or saline with a nasal spray. During fMRI scanning, participants will then
      undergo an observational learning phase, where the study participants will learn the
      experience of analgesia in another person through a video, and a testing phase, where
      participants will perceive painful stimulations with the same cues as the observational
      phase. The comparison of the vasopressin group and the saline group will allow us to
      investigate how vasopressin influences behavioral effects of observational learning on pain
      perception as well as its effect on the neural processing of observational learning.

      A better understanding of how the human brain processes observationally-induced analgesia
      would allow us to improve the therapeutic context of pain treatments by increasing the
      contextual factors which help patients cope with pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this research is to investigate how vasopressin (AVP) influences the neural
      mechanisms associated with observationally-induced analgesia. More specifically, the
      investigators will determine how observing another person experiencing analgesia shapes
      subsequent behavioral and neural responses to painful stimulations.

      Aim 1: To investigate how AVP influences the neural mechanisms associated with
      observationally-induced analgesia.

      Hypothesis 1: The investigators expect that AVP will boost activation in brain regions
      involved in social cognition.

      The overall objective is to determine the effect of AVP on brain mechanisms associated with
      observationally-induced analgesia. This experiment has a between-subject study design.
      Participants will be randomized into an AVP group and a control group. The experimenter as
      well as the participant will be blinded regarding the allocation of the participant.
      Participants in the AVP group will receive intranasal AVP and the participants in the control
      group will receive intranasal saline before the fMRI experiment. Participants have 50% chance
      of being placed in either group. The experiment in the fMRI scanner is divided into two
      phases: an observational phase, in which participants will observe a video of a demonstrator
      experiencing analgesia, and a testing phase, in which study participants will receive heat
      pain to investigate how pain perception was influenced. During both phases there will be a
      placebo condition (pain with the expectation of having received a treatment) and a control
      condition (pain without the expectation of having received a treatment). All participants
      will complete both phases, including the observational and testing phase.

      Expectancy of analgesia related to the act of receiving a treatment (e.g. a painkiller) can
      reduce pain perception, even if this treatment is in fact an inert substance (e.g. placebo).
      Expectancies about analgesic treatments can be acquired in several different ways, including
      direct experience of analgesia (i.e. the patient learns that after taking a specific drug,
      pain will decrease), verbal instructions (i.e. the doctor tells the patient that a specific
      drug will reduce pain) or social observation (i.e. the patient observes pain relief in
      another patient after this patient took a specific drug).

      The direct experience of pain relief in the context of treatment cues (i.e. conditioning)
      reduces subsequent pain perception when the same treatment cues are present. The neural
      underpinnings of how treatment expectancies are acquired during conditioning have been
      investigated previously. These studies indicate that the prefrontal cortex is involved in
      learning treatment expectations in the context of conditioned analgesic effects.

      However, these expectancies can also be acquired by observing others. Our group was the first
      to demonstrate that analgesia can be triggered by observing another person that experiences
      analgesia. This finding has been corroborated with additional studies by our group and other
      groups. In these experiments, participants acquire expectancies of analgesia not by
      experiencing pain relief themselves, but rather by observing another person (the
      demonstrator) experiencing analgesia after receiving a certain analgesic treatment (actually
      a sham treatment). These placebo manipulations generate expectancies which lead to placebo
      effects of similar sizes that those shown through direct experience via conditioning
      paradigms.

      Even though previous research has focused on the direct experience of pain relief within a
      treatment context, social psychology suggests that most human behaviors are in fact modulated
      by sociality and learned by observing others. The investigators recently established a
      paradigm to investigate neural mechanisms of observational learning in placebo analgesia. The
      preliminary data analysis (unpublished data) suggests that while participants are observing
      someone else experiencing less pain due to an analgesic treatment, brain regions associated
      with mentalizing processes such as left and right temporoparietal junction (TPJ) and medial
      prefrontal cortex (mPFC) show increased activation. However, the underlying neurotransmitter
      systems are unknown. Here, the investigators aim to investigate how AVP modulates this
      network of brain regions. AVP is a likely candidate system, because recently it has been
      associated with placebo analgesia by my current mentor's lab, is involved in controlling a
      wide variety of social behaviors, and has been shown to critically modulate TPJ activity. The
      investigators expect that AVP will lead to increased activation of the mentalizing network
      during observational learning, and therefore, to increased placebo analgesia as a result of
      the observational learning. In order to investigate this, the investigators will perform a
      similar observational learning study in a group receiving intranasal AVP and a control group
      receiving intranasal saline.

      Background: Clinical outcomes are not just related to pharmacological substances, but also to
      the context in which a treatment is given as well as expectancies, fears, desires and beliefs
      of the patient. The beneficial effects on health related outcome changes due to the treatment
      context and not due to specific actions of a drug are known as placebo effects. In the field
      of pain, the reduction of pain perception due to placebo effects is called placebo analgesia
      or expectancy-induced analgesia.

      Previous research shows that in placebo analgesia, informational cues of the treatment
      context generate the expectancy of pain relief due to a treatment. These expectations can be
      acquired through several ways, including learning through direct experience (i.e.
      conditioning), verbal instruction or observation of others.

      Several studies investigated the influence of direct experience of analgesia using
      conditioning paradigms on placebo effects. These studies show that conditioning creates more
      robust placebo effects than verbal suggestions alone and that the magnitude of experienced
      pain relief and the duration influence subsequent placebo effects.

      On the neural level, placebo effects on pain perception are mediated by the descending pain
      modulatory system. Endogenous opioids are involved in the pain descending modulation systems,
      and placebo analgesia can be substantially reduced by opioid antagonists. Several studies
      implicate functional connectivity between the rostral anterior cingulate and the
      periaqueductal gray, a region critical for descending pain modulation, and placebo analgesia.
      Additionally, there is considerable evidence that prefrontal regions, especially the
      dorsolateral prefrontal cortex (DLPFC), are critically involved in placebo analgesia. The
      prefrontal cortex consistently shows higher activations related to the anticipation of
      analgesia and experience of pain relief induced by a placebo manipulation, and is involved in
      the acquisition of expectancies during conditioning of placebo analgesia.

      Therefore the current understanding is that the prefrontal cortex maintains and updates
      expectancies regarding pain, and that these prefrontal regions influence the experience of
      pain by activating the descending pain modulatory system.

      The influence of social learning on placebo analgesia has been investigated to a lesser
      degree. Recent research suggests that placebo analgesia can also be induced by observational
      learning, however, the neural neurotransmitter systems underpinning observationally-induced
      placebo analgesia have not yet been investigated.

      Rationale: To harness the placebo effects in clinical contexts, it is important to understand
      how placebo effects arise and are maintained. Previous neuroscience research has primarily
      focused on conditioning paradigms, however human behaviors are affected by social learning.
      Social learning refers to learning about the environment due to information gained by
      observing others. Our overall hypothesis is that AVP will increase neural activation in
      regions related to social cognition during observational learning. Our objective is to
      determine the interplay of AVP and observationally-induced analgesia using an fMRI approach.
      fMRI is a noninvasive technique to measure changes in blood oxygenation in the brain enabling
      us to draw inferences about the localization and extend of neural activation associated with
      specific events and cues including the perception of experimental painful stimulations and
      modulation. The investigators designed an experiment to be performed behaviorally and with
      fMRI measurements in order to determine the interplay of AVP and observationally-induced
      analgesia.

      Significance: This experiment will advance our understanding of endogenous processes
      associated with observationally-induced analgesia and the factors that influences pain
      processing. A better understanding of how treatment expectancies, formed through social
      observation, influence the individual experience of pain is significant in several ways.
      First, it will allow a better understanding of the contextual factors shaping pain and
      responses to treatments in clinical settings. Second, knowledge about the neural processes
      associated with endogenous pain relief might lead to novel developments in pain therapeutic
      strategies. Third, the investigators anticipate generating findings that will advance our
      knowledge of how cognitive processes (i.e. expectancy) are represented in the brain and how
      these factors influence human social behaviors.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 15, 2018</start_date>
  <completion_date type="Anticipated">August 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This experiment has a between-subjects design. Participants will be randomized into two groups: AVP and control. Both the experimenter and participant will be blinded to the group allocation. Participants have 50%/50% chance of being placed in either group. Participants in the AVP group will receive intranasal AVP and the participants in the control group will receive intranasal saline before the fMRI experiment. The experiment in the fMRI scanner is divided into two phases: an observational phase in which participants will observe a video of a demonstrator experiencing analgesia and a testing phase in which study participants will receive heat pain to investigate how their pain perception. During both phases there will be a placebo condition (pain with the expectation of having received a treatment) and a control condition (pain without the expectation of having received a treatment). All participants will complete both phases, including the observational and testing phase.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Randomization will be performed/maintained by the University of Maryland Medical Center Pharmacy. Blind will only be broken in case of a potential medical emergency during the experiment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Neural outcome</measure>
    <time_frame>Day 2</time_frame>
    <description>Blood oxygenation level dependent (BOLD) responses will allow the identification of relative activation/deactivation in the brain as result of events (e.g. painful stimulations) that will be given during the experiment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain ratings</measure>
    <time_frame>Days 1 (calibration) and 2 (test)</time_frame>
    <description>Participants will provide their pain on a Visual Analogue Scale raging from 0=no pain to 100= maximum unbearable pain. Normal value will be absence of pain.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Implicit association test (IAT)</measure>
    <time_frame>Day 1</time_frame>
    <description>Implicit racial bias measure</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>ADH</condition>
  <condition>Arginine Vasopressin</condition>
  <condition>Antidiuretic Hormone</condition>
  <condition>Placebo</condition>
  <condition>Analgesia</condition>
  <condition>Social Behavior</condition>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Under direction of a research team member, participants will self-administer intranasal normal saline shortly before beginning the fMRI experiment.
Investigators, staff, and participants were blinded to the treatment options. Each of the agents will be administrated by means of a nasal spray. Participants will be instructed by a nurse/PI to self-administer the nasal spray as follows: one spray in each nostril alternating sides, 30 seconds apart for a total of two sprays per nostril.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arginine vasopressin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Under direction of a research team member, participants will self-administer intranasal vasopressin shortly before beginning the fMRI experiment. The of AVP will be 40IU. The quantity per unit (1 mL) of Arg8-vasopressin synthetic, manufactured by Polypeptide Group Inc. (http://www.polypeptide.com) was 0.323 mg. This amount was diluted in 0.9% sodium chloride (B. Broun Medical Inc.).
A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment. Participants will be first stratified for sex and then randomized to saline (0.4 mL) or vasopressin (40 IU) group, respectively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arginine vasopressin</intervention_name>
    <description>Intranasal vasopressin will be administered shortly before the fMRI experiment.</description>
    <arm_group_label>Arginine vasopressin</arm_group_label>
    <other_name>Arg8-vasopressin synthetic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Intranasal saline will serve as a placebo for participants in the Saline Arm</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ( 18-55 years old)

          -  English speaker (written and spoken)

        Exclusion Criteria:

          -  Cardiovascular, neurological diseases, pulmonary abnormalities, kidney disease, liver
             disease, degenerative neuromuscular disease, history of cancer within past 3 years

          -  Any history of chronic pain disorder or currently in pain

          -  Severe psychiatric condition (e.g. schizophrenia, bipolar disorders, mania, autism)
             and /or psychiatric condition leading to treatment and/or hospitalization within the
             last 3 years.

          -  Family (first degree) history of mania, schizophrenia, or other psychoses

          -  Lifetime alcohol/drug dependence or alcohol/drug abuse in past 3 months

          -  Pregnancy or breast feeding

          -  Color-blindness

          -  Impaired, uncorrected hearing

          -  History of angioedema

          -  High blood pressure (above 140 mmHg) or symptomatic low blood pressure

          -  History of fainting

          -  Left handed

          -  Allergies or sensitivities to creams, lotions or food coloring

          -  Any non-organic implant or any non-removable metal device (e.g. pacemaker, cochlear
             implants, stents, surgical clips, non-removable piercings)

          -  Any prior eye injury or the potential of a foreign body in the eye (e.g. worked in
             metal fields)Persisting functional impairment due to a head trauma

          -  Fear of closed spaces

          -  Any other contraindications for MRI (e.g. large tattoos on head and neck)

          -  Previously participated in a &quot;Pain Perception in the Brain&quot; Study

          -  Failed drug test (testing for opiates, cocaine, methamphetamines, amphetamines and
             THC)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luana Colloca, MD/PHD/MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland Baltimore School of Nursing</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Research Coordinator</last_name>
    <phone>410-706-5975</phone>
    <email>nrscollocalab@umaryland.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nathaniel Haycock, MS</last_name>
    <email>nhaycock@umaryland.edu</email>
  </overall_contact_backup>
  <reference>
    <citation>Colagiuri B, Schenk LA, Kessler MD, Dorsey SG, Colloca L. The placebo effect: From concepts to genes. Neuroscience. 2015 Oct 29;307:171-90. doi: 10.1016/j.neuroscience.2015.08.017. Epub 2015 Aug 10. Review.</citation>
    <PMID>26272535</PMID>
  </reference>
  <reference>
    <citation>Colloca L, Benedetti F. Placebo analgesia induced by social observational learning. Pain. 2009 Jul;144(1-2):28-34. doi: 10.1016/j.pain.2009.01.033. Epub 2009 Mar 10.</citation>
    <PMID>19278785</PMID>
  </reference>
  <reference>
    <citation>Colloca L, Pine DS, Ernst M, Miller FG, Grillon C. Vasopressin Boosts Placebo Analgesic Effects in Women: A Randomized Trial. Biol Psychiatry. 2016 May 15;79(10):794-802. doi: 10.1016/j.biopsych.2015.07.019. Epub 2015 Aug 4.</citation>
    <PMID>26321018</PMID>
  </reference>
  <reference>
    <citation>Schenk LA, Sprenger C, Geuter S, BÃ¼chel C. Expectation requires treatment to boost pain relief: an fMRI study. Pain. 2014 Jan;155(1):150-7. doi: 10.1016/j.pain.2013.09.024. Epub 2013 Sep 26.</citation>
    <PMID>24076046</PMID>
  </reference>
  <reference>
    <citation>Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL. Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci. 2002 Jun;5(6):514-6.</citation>
    <PMID>11992114</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2018</study_first_submitted>
  <study_first_submitted_qc>February 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2018</study_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland</investigator_affiliation>
    <investigator_full_name>Luana Colloca</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>Healthy Volunteers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Insipidus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasopressins</mesh_term>
    <mesh_term>Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The BDI II question (#9) asks the participant to rate their feelings of suicidal thoughts or wishes. The research staff will review each participant's response after completion at each study visit to assess if the participant shows the potential for harm to self or others. Any participant who scores a 2 or 3 on that item or has a total score of 29 or more will be referred to their provider for follow-up. The investigators will call 911 for any participant who experiences a medical or psychological emergency during the experiment. Similarly, the MASQ item 61 asks about &quot;Thought about death or suicide&quot;. In case of a positive answer, participants will be referred to their provider for follow-up.
The only other information that will be shared with the participant is incidental findings from the MRI. Participants will be referred to their primary care physician for follow up. A copy of the MRI scan on disk can be provided to the participant.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

